Literature DB >> 7113697

A comparative longitudinal study on sex hormone binding globulin capacity during estrogen replacement therapy.

S Helgason, J E Damber, M G Damber, B von Schoultz, G Selstam, R Södergård.   

Abstract

An aqueous two-phase equilibrium partition system was used to assay SHBG-binding capacity. Sera from groups of postmenopausal women before and during unopposed estrogen replacement therapy were analyzed. The induction of SHBG showed considerable differences between different estrogens. Ethinyl-estradiol in a daily dose of 0.05 mg gave a 70% increase in the serum concentration of this liver derived protein. Estradiol-17 beta, 2 mg daily and estrone sulphate 1.25 mg gave moderate changes, whereas estriol in different doses had no effect. SHBG induction may reflect estrogen overtreatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7113697     DOI: 10.3109/00016348209156536

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

1.  Confounding effects of hormone replacement therapy in protein biomarker studies.

Authors:  Sharon J Pitteri; Samir M Hanash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-29       Impact factor: 4.254

2.  Urine excretion of androgen hormones in professional racing cyclists.

Authors:  M Maynar; M J Caballero; P Mena; C Rodríguez; R Cortés; J I Maynar
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1994

3.  Effects of a continuous estrogen-progestogen therapy for climacteric symptoms on circulating sex steroids and gonadotrophins.

Authors:  L A Mattsson; L Abrahamsson; G Cullberg; G Samsioe
Journal:  Arch Gynecol       Date:  1983

4.  Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings.

Authors:  Hiroyuki Katayama; Sophie Paczesny; Ross Prentice; Aaron Aragaki; Vitor M Faca; Sharon J Pitteri; Qing Zhang; Hong Wang; Melissa Silva; Jacob Kennedy; Jacques Rossouw; Rebecca Jackson; Judith Hsia; Rowan Chlebowski; Joann Manson; Samir Hanash
Journal:  Genome Med       Date:  2009-04-29       Impact factor: 11.117

Review 5.  Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary.

Authors:  Mark J Messina; Charles E Wood
Journal:  Nutr J       Date:  2008-06-03       Impact factor: 3.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.